GuoLine Advisory Pte Ltd Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GuoLine Advisory Pte Ltd increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,360 shares of the biopharmaceutical company’s stock after purchasing an additional 14,300 shares during the quarter. Regeneron Pharmaceuticals makes up about 3.4% of GuoLine Advisory Pte Ltd’s portfolio, making the stock its 13th biggest position. GuoLine Advisory Pte Ltd’s holdings in Regeneron Pharmaceuticals were worth $33,024,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $39,000. Finally, Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 3.6 %

REGN stock opened at $690.87 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $75.92 billion, a P/E ratio of 17.10, a PEG ratio of 2.19 and a beta of 0.10. The company’s 50-day simple moving average is $746.43 and its 200-day simple moving average is $956.18.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,032.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.